Navigation Links
Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
Date:11/27/2007

29 presentations on ZEVALIN(R) scheduled at American Society of Hematology

(ASH) Annual Meeting

SEATTLE, Nov. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced it intends to utilize the results of the phase III first-line indolent trial of ZEVALIN (Ibritumomab Tiuxetan), known as the FIT trial, for submission to the United States Food and Drug Administration (FDA) for potential approval in the consolidation of first remissions following chemotherapy for patients with follicular non-Hodgkin's lymphoma (NHL). CTI has signed an agreement to acquire the U.S. marketing, sales and development rights to ZEVALIN, however, that acquisition has not yet been completed and remains subject to closing conditions, including obtaining certain third party consents, and until the transaction is closed, ZEVALIN remains a product and trademark of Biogen Idec, Inc. CTI expects the acquisition to close by the end of November and as such is hosting a booth at the ASH meetings. The results of the FIT trial will be presented in an oral session on Monday, December 10 at 3:30 p.m. (Eastern) at the 49th Annual Meeting of the American Society of Hematology (ASH), being held December 8-11, 2007 in Atlanta.

Bayer Schering recently announced it had submitted the FIT results to the EMEA for consideration for a new indication for the product in the European Union (EU). "With our commercial leadership now on board we look forward to the prospects of working closely with Bayer-Schering in providing the support for the Zevalin brand that this important therapeutic deserves," said James A. Bianco, M.D., President and CEO of CTI.

Other presentations at ASH, includ
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Health Plans Increase Use of Health Incentives
11. Area Health Care Providers Announce Plans to Integrate Services

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...TON, W.Va., Dec. 4 UniCare Health ...nd West Virginia Radio Corporation will be holding...-based Mountain Mission. Several local celebrities...r, Pro Bass Fisherman Jeremy Starks, Secretary of ...n will participate in the two-day food drive. ,...
(Date:12/4/2009)...OMA CITY, Dec. 4 PD-Rx P...ounced revenue of $5,012,334 for the first quarter... same period last year. Operating income and net ...respectively, each a 70% decrease over the same pe...ecrease in pharmacy sector sales. This trend is e...
(Date:12/4/2009)... dramatic weight loss can be an effective way to i... at the Swedish medical university Karolinska Inst... the study began benefited most from weight loss. ... an effective treatment strategy for sleep apnoea ...earchers involved in the study. , Sleep apnoea ...
(Date:12/4/2009)... Lexi-Comp,s multi-language patient educati... establish standards for language access in health...son, OH (PRWEB) December 5, 2009 -- Lexi-Comp, Inc...olutions, and patient education materials for heal... effective communication between the health care p...
(Date:12/4/2009)...indication they understand what 2-D images represe...HealthDay News) -- Monkeys can recognize photograp...an both detect differences in faces and figure out..., The study also shows that capuchin monkeys ca...aph, the scientists authors noted. , The findin...
Breaking Medicine News(10 mins):Health News:UniCare, Walmart Organize Circle of Hope To Help Mountain Mission Meet Increased Demand for Assistance 2Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Weight-loss proves effective cure for sleep apnea 2Health News:Weight-loss proves effective cure for sleep apnea 3Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
...an be made quickly, researchers say , , WE...ve succeeded in developing a whole-virus bird flu ...an the one currently approved for human use and al...ceiving a second dose of the vaccine, CELVAPAN, ma...
...increasing demand for pork produced without antibi...carry bacteria and parasites associated with food-...mparison of swine raised in antibiotic-free and co...s on conventional farms, which remain indoors and ...
...uildup of plaque in the brain, study says , ... of drugs called gamma-secretase modulators shows ...study suggests. , A hallmark of Alzheimer,s is so-...n that stick together and form clumps. At the same...
...suction Patients Model Top Designers Summer Ware ...al Life Makeover Patients To Enjoy "Coming Out in ...akeover patients of New,York area doctors wearing ...Bethpage State Park-Carlyle on the Green,on 99 Qua...
...Potential Salmonella Risk, APTOS, Calif., June 11...rtain raw tomatoes due to possible,contamination w...il,(TomatoWellness.com) emphasized today that heat...omato products, heat,reaches at least 160 degrees....
...E:,CNO) announced that Matthew J. Zimpfer has been...unsel of Conseco. Zimpfer, who had been serving as...im Prieur., (Photo: http://www.newscom.com/cgi-b...said. "He is a proven,leader and his breadth of kn...
Other Medicine News:Health News:New Bird Flu Vaccine Shows Promise 2Health News:New Bird Flu Vaccine Shows Promise 3Health News:New Bird Flu Vaccine Shows Promise 4Health News:Pigs raised without antibiotics more likely to carry bacteria, parasites 2Health News:Pigs raised without antibiotics more likely to carry bacteria, parasites 3Health News:Pigs raised without antibiotics more likely to carry bacteria, parasites 4Health News:New Class of Drugs May Fight Alzheimer's 2Health News:New Class of Drugs May Fight Alzheimer's 3Health News:Clarity Needed Amidst Tomato Contamination Confusion 2
(Date:12/3/2009)...rstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ..., Tissue Repair Company, submitted a 510(k) premar...g Administration (FDA) seeking marketing clearance...n positive data from the Company,s recently comple...ssion with the FDA covers Excellagen XL(TM) and E...
(Date:12/3/2009)...- Alzheimer,s disease (AD) is one of the most hear...eversible, progressive brain disease slowly destro...the ability to carry out the simplest tasks. The m...D affects as many as 2.4 million to 4.5 million Am...ing. ,, (Logo: http://www.newscom.com/cgi-bi...
(Date:12/3/2009)...e-FirstCall/ -- ULURU Inc. (NYSE ULU) announc... of the major pharmaceutical distributors in the U... its suppliers and has placed its first significan...al delivers a comprehensive offering of medical-su... technology-related services to the alternate site...
Breaking Medicine Technology:Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Alzheimer's Research May Lead to Preventing the Debilitating Disease 2Alzheimer's Research May Lead to Preventing the Debilitating Disease 3ULURU Inc. Obtains Status of Approved Supplier With McKesson. 2California Nurses NNOC Nations Largest Nurses Organization Unanimously Endorses Joining RN Super Union 56856 1California Nurses NNOC Nations Largest Nurses Organization Unanimously Endorses Joining RN Super Union 56856 2Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes 4966 1Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes 4966 2An invitation to the nations premier aging conference 56853 1An invitation to the nations premier aging conference 56853 2
...lif., May 31, 2007 /PRNewswire-FirstCall/ -- The,f...how positive,results for Kamada,s Alpha-1 Antitryp...ivered with PARI,s eFlow electronic,nebulizer for ...iency. Dosage levels studied resulted in good safe...way to continued drug,development of aerosolized A...
...d., June 01, 2007 /PRNewswire-FirstCall/ --,EntreM... developing,therapeutics for the treatment of canc...tation of preclinical results for its Aurora,kinas...were,presented during oral and poster presentation...s in Drug Discovery Conference,being held May 31 -...
Other Medicine Technology:PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 2PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 3EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 2EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 3
Crystalline ActFix
Fineline II Sterox EZ
CapSureFix
...s are small profile endocardial permanent pacing l...n helix. With a lead body size of only 4.8 F and a...allest extendable/retractable bipolar pacing lead ...e-formed J configurations, Physique leads are idea...
Medicine Products: